An injectable antibody that sharply lowers "bad" cholesterol by freeing the liver to clear more of it. Best established for large, dependable cholesterol and particle lowering; in people who have had a heart event it also lowers the chance of further heart attacks and strokes. Side effects are generally mild. Value depends heavily on individual risk. (Full Review)

Protocol

Standard Dosing

75 mg every 2 weeks

Subcutaneous injection to start

Dose Escalation

150 mg every 2 weeks

If more lowering needed after 4–8 weeks

Monthly Alternative

300 mg every 4 weeks

Two 150 mg injections at one sitting

Time to effect

LDL-C Onset

1–2 weeks

Cholesterol begins falling

Near-Maximal Effect

~4 weeks

Near-maximal LDL-C reduction

Confirm Response

4–8 weeks

Follow-up lipid panel

Benefits

High: Potent LDL cholesterol & ApoB reduction; reduction in major cardiovascular events

Medium: All-cause mortality reduction; lipoprotein(a) reduction

Low: Coronary plaque regression & stabilization; LDL control in familial hypercholesterolemia & statin intolerance

Speculative: Potentiation of cancer immunotherapy; anti-inflammatory & alcohol-associated liver effects

Contraindications

Serious hypersensitivity to alirocumab

Pregnancy and breastfeeding

Key Interactions

Redundant PCSK9-targeting drugs (evolocumab, inclisiran)

Additive LDL-lowering supplements (psyllium, beta-glucan, plant sterols/stanols, red yeast rice, berberine, bergamot)

Risk & Side Effects

High: Injection-site reactions; upper respiratory & influenza-like symptoms

Medium: Hypersensitivity & allergic reactions; neurocognitive events

Low: Uncertain long-term effects of very low LDL-C

Speculative: New-onset diabetes / dysglycemia; rare immune-mediated reactions

Monitoring

Marker	Target	Why
LDL-C	<70 mg/dL secondary prevention; many longevity clinicians target <55 mg/dL	Primary target and main driver of response
ApoB	<60–80 mg/dL; aggressive <60 mg/dL	Best single measure of atherogenic particle burden
Lp(a)	<30 mg/dL (<75 nmol/L)	Identifies inherited residual risk the drug partly lowers
Non-HDL cholesterol	<100 mg/dL; aggressive <80 mg/dL	Captures all non-protective cholesterol in one number
Fasting glucose / HbA1c	Glucose <100 mg/dL; HbA1c <5.4%	Screens for the unproven dysglycemia concern
hs-CRP	<1.0 mg/L	Gauges residual vascular inflammation

Cadence: Re-check lipid panel and ApoB about 4–8 weeks after initiation or dose change, then every 6–12 months once stable

Qualitative Assessment

Injection tolerance and any site reactions
Any flu-like or upper-respiratory symptoms after dosing
Subjective cognitive clarity and memory
Adherence to the every-2-week or monthly schedule
In former statin users, resolution of any prior muscle aches

Alirocumab for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment